Trimethoprim-Sulfamethoxazole or Doxycycline for Skin and Soft Tissue Infections

This study has been completed.
Sponsor:
Information provided by:
University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT00428818
First received: January 29, 2007
Last updated: NA
Last verified: January 2007
History: No changes posted
  Purpose

Background: In many communities, skin and soft tissue infections (SSTI) with MRSA have become more prevalent than infections with β-lactam susceptible bacteria. This has necessitated altered empiric antimicrobial therapy of SSTI to cover MRSA.

Objective: To evaluate empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient SSTI in an area of high MRSA prevalence.

Design: Randomized, prospective, open-label investigation. Setting: Emergency Department of Parkland Hospital in Dallas, Texas. Patients: Adults with SSTI. Intervention: Empiric oral therapy with trimethoprim-sulfamethoxazole (160 mg/800 mg, twice daily) or doxycycline (100 mg, twice daily).

Measurement: The primary endpoint was clinical failure defined as hospitalization or change in antibiotic therapy over the 10 to 14 days after initial emergency department evaluation.


Condition Intervention
Infection
Drug: trimethoprim-sulfamethoxazole or doxycycline

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Empiric Therapy With Trimethoprim-Sulfamethoxazole or Doxycycline for Outpatient Skin and Soft Tissue Infections in an Area of High MRSA Prevalence: A Prospective Randomized Trial

Resource links provided by NLM:


Further study details as provided by University of Texas Southwestern Medical Center:

Primary Outcome Measures:
  • The primary endpoint was clinical failure defined as hospitalization or change in antibiotic therapy over the 10 to 14 days after initial emergency department evaluation.

Estimated Enrollment: 75
Study Start Date: August 2005
Estimated Study Completion Date: July 2006
Detailed Description:

As MRSA in more likely to be isolated from a SSTI than is a β-lactam susceptible organism at Parkland Hospital in Dallas, Texas, we performed a randomized, prospective, open-label investigation in our emergency department to determine the efficacy of empiric therapy using off-patent oral antibiotics (trimethoprim-sulfamethoxazole 160 mg/800 mg twice daily or doxycycline 100 mg twice daily for 7 days) for the outpatient treatment of SSTI abscesses, requiring wound packing after incision and drainage but not requiring hospitalization. Only SSTI requiring wound packing were enrolled to eliminate the inclusion of smaller SSTI not requiring wound packing.

This investigation was approved by The University of Texas Southwestern Medical Center Institutional Review Board and included adults (≥ 18 years old) who were willing and able to provide informed consent. Inclusion criteria included being able to return for follow-up at 2 to 5 days after enrollment and being accessible by telephone for follow-up assessment at 10 to 14 days and 28 to 35 days after enrollment. Exclusion criteria excluded patients with contraindications or history of hypersensitivity reaction to any of the study treatment regimens, an infected prosthesis or device, concomitant bacteremia or deep infections (e.g. osteomyelitis, necrotizing fasciitis, endocarditis), diabetic foot infections, known immunodeficiency, pregnant or breastfeeding, requirement of additional antimicrobial agents, and those who did not obtain assigned antibiotics.

The primary endpoint of this study was clinical failure defined as subsequent hospital admission, administration of intravenous antibiotics, or change in oral antibiotics over a period of 10-14 days after initial emergency department presentation. Repeated outpatient incision and drainage of the SSTI at 2 to 5 days after enrollment was not considered a clinical failure, if antibiotics were not changed and intravenous antibiotics were not administered. The trial enrolled patients from October 2005 to May 2006. Method of randomization was by generation of random numbers using www.randomizer.org, and alternately assigning these to the two treatment groups, and then sorting the numbers consecutively to determine the sequence of assigning treatment group to consecutively recruited patients. Statistical analysis was performed with SigmaStat 3.0 software (SPSS Inc., Chicago, Illinois). This investigation had no external funding.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Outpatient treatment of SSTI abscesses, requiring wound packing after incision and drainage but not requiring hospitalization.
  • Adults (≥ 18 years old) who were willing and able to provide informed consent.
  • Able to return for follow-up at 2 to 5 days after enrollment and being accessible by telephone for follow-up assessment at 10 to 14 days and 28 to 35 days after enrollment.

Exclusion Criteria:

  • Exclusion criteria excluded patients with contraindications or history of hypersensitivity reaction to any of the study treatment regimens, an infected prosthesis or device, concomitant bacteremia or deep infections (e.g. osteomyelitis, necrotizing fasciitis, endocarditis), diabetic foot infections, known immunodeficiency, pregnant or breastfeeding, requirement of additional antimicrobial agents, and those who did not obtain assigned antibiotics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00428818

Sponsors and Collaborators
University of Texas Southwestern Medical Center
Investigators
Study Director: Robert D Hardy, MD University of Texas Southwestern Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00428818     History of Changes
Other Study ID Numbers: 072005-011
Study First Received: January 29, 2007
Last Updated: January 29, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by University of Texas Southwestern Medical Center:
MRSA

Additional relevant MeSH terms:
Infection
Communicable Diseases
Soft Tissue Infections
Doxycycline
Trimethoprim
Trimethoprim-Sulfamethoxazole Combination
Sulfamethoxazole
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents, Urinary
Renal Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014